Literature DB >> 18758474

Nanoparticle therapeutics: an emerging treatment modality for cancer.

Mark E Davis1, Zhuo Georgia Chen, Dong M Shin.   

Abstract

Nanoparticles--particles in the size range 1-100 nm--are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758474     DOI: 10.1038/nrd2614

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  1000 in total

1.  Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].

Authors:  Hui Ding; Satoshi Inoue; Alexander V Ljubimov; Rameshwar Patil; Jose Portilla-Arias; Jinwei Hu; Bindu Konda; Kolja A Wawrowsky; Manabu Fujita; Natalya Karabalin; Takako Sasaki; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  A rapid pathway toward a superb gene delivery system: programming structural and functional diversity into a supramolecular nanoparticle library.

Authors:  Hao Wang; Kan Liu; Kuan-Ju Chen; Yujie Lu; Shutao Wang; Wei-Yu Lin; Feng Guo; Ken-ichiro Kamei; Yi-Chun Chen; Minori Ohashi; Mingwei Wang; Mitch André Garcia; Xing-Zhong Zhao; Clifton K-F Shen; Hsian-Rong Tseng
Journal:  ACS Nano       Date:  2010-10-26       Impact factor: 15.881

Review 3.  Developing therapeutic microRNAs for cancer.

Authors:  A G Bader; D Brown; J Stoudemire; P Lammers
Journal:  Gene Ther       Date:  2011-06-02       Impact factor: 5.250

4.  Gold Nanoparticles for Radiation Enhancement in Vivo.

Authors:  Samana Shrestha; Leon N Cooper; Oleg A Andreev; Yana K Reshetnyak; Michael P Antosh
Journal:  Jacobs J Radiat Oncol       Date:  2016-04-27

5.  Robust manufacturing of lipid-polymer nanoparticles through feedback control of parallelized swirling microvortices.

Authors:  Michael J Toth; Taeyoung Kim; YongTae Kim
Journal:  Lab Chip       Date:  2017-08-08       Impact factor: 6.799

6.  Dimeric Drug Polymeric Micelles with Acid-Active Tumor Targeting and FRET-Traceable Drug Release.

Authors:  Xing Guo; Lin Wang; Kayla Duval; Jing Fan; Shaobing Zhou; Zi Chen
Journal:  Adv Mater       Date:  2017-12-06       Impact factor: 30.849

7.  Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy.

Authors:  Dawei Ding; Xiaolei Tang; Xiaoli Cao; Jinhui Wu; Ahu Yuan; Qian Qiao; Jing Pan; Yiqiao Hu
Journal:  AAPS PharmSciTech       Date:  2013-11-28       Impact factor: 3.246

8.  Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation.

Authors:  Kevin G Reuter; Jillian L Perry; Dongwook Kim; J Christopher Luft; Rihe Liu; Joseph M DeSimone
Journal:  Nano Lett       Date:  2015-09-30       Impact factor: 11.189

Review 9.  Hybrid nanoparticles for combination therapy of cancer.

Authors:  Chunbai He; Jianqin Lu; Wenbin Lin
Journal:  J Control Release       Date:  2015-09-24       Impact factor: 9.776

10.  Nanoparticles functionalized with collagenase exhibit improved tumor accumulation in a murine xenograft model.

Authors:  Surya Murty; Taylor Gilliland; Peter Qiao; Tate Tabtieng; Elizabeth Higbee; Ajlan Al Zaki; Ellen Puré; Andrew Tsourkas
Journal:  Part Part Syst Charact       Date:  2014-12       Impact factor: 3.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.